Evaluation of the Antihyperalgesic Effect of Tapentadol in Two Human Experimental Models

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Ralf Baron, University of Schleswig-Holstein
ClinicalTrials.gov Identifier:
NCT01615510
First received: June 6, 2012
Last updated: March 25, 2014
Last verified: March 2014
  Purpose

MOR-NRI like Tapentadol are expected to reduce signs and symptoms of central sensitisation besides effectively reducing pain intensity in pain. Human pain surrogate models can serve in this proof-of-concept study to further elucidate this assumption.


Condition Intervention Phase
Pain
Hyperalgesia
Allodynia
Drug: Tapentadol immediate release
Drug: placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of the Antihyperalgesic Effect of Tapentadol in Two Human Experimental Models of: 1) Cold and Mechanical Hyperalgesia Evoked by Topical High-concentration Menthol , 2) Heat and Mechanical Hyperalgesia by Capsaicin.

Resource links provided by NLM:


Further study details as provided by University of Schleswig-Holstein:

Primary Outcome Measures:
  • QST parameters [ Time Frame: period 1 - period 2 (approx. 18 days) ] [ Designated as safety issue: No ]

    The primary objective is to evaluate the antihyperalgesic effect of a single dose of Tapentadol immediate release (IR) in two human experimental models:

    1. cold pain threshold (menthol only),
    2. heat pain thresholds (capsaicin only),
    3. mechanical pain threshold
    4. mechanical pain sensitivity,
    5. dynamic mechanical allodynia,
    6. area of dynamic mechanical allodynia and
    7. area of pinprick-hyperalges


Enrollment: 24
Study Start Date: October 2012
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Capsaicin (topical)
300 µL of 0.6% capsaicin in 45% ethanol, topically applied on the forearm intervention: tapentadol immediate release or placebo
Drug: Tapentadol immediate release
100 mg, single administration
Other Name: Palexia IR
Drug: placebo
placebo, single administration
Other Name: P Lichtenstein
Experimental: Menthol (topical)
1000 µL of 40% menthol in 90% ethanol, topically applied on the forearm intervention: tapentadol immediate release or placebo
Drug: Tapentadol immediate release
100 mg, single administration
Other Name: Palexia IR
Drug: placebo
placebo, single administration
Other Name: P Lichtenstein

Detailed Description:

To evaluate exploratory the antihyperalgesic effect of a single dose of Palexia® IR (Tapentadol) in two human experimental models of 1) cold and mechanical (pinprick) hyperalgesia after topical application of menthol at high-concentration [40%] and 2) of heat and mechanical (pinprick) hyperalgesia by topical applied capsaicin [0.6%] in comparison to placebo. Therefore, cold, heat and mechanical hyperalgesia and allodynia will be determined by parameters of the Quantitative Sensory Testing (QST). These parameters are cold and heat pain thresholds, mechanical pain threshold and sensitivity as well as dynamic mechanical allodynia. Further, the areas of dynamic mechanical allodynia and pinprick-hyperalgesia will be determined at each timepoint of QST-assessement.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Provided written informed consent to participating in the trial.
  2. Caucasian, female or male, and aged 18 years to 55 years, inclusive.
  3. Body mass index between 18.5 kg/m2 and 30 kg/m2, inclusive, with a lower body weight limit of 50 kg.
  4. In good health as determined by medical history, physical examination, 12-lead ECG, vital signs (pulse rate, respiratory rate, systolic and diastolic blood pressure), oxygen saturation, and laboratory monitoring (hematology, clinical chemistry, clotting, and urinalysis).
  5. Subjects must be able to feel thermal and mechanical sensation (cold, warm, sharp, unpleasant sensation) on normal skin (at the forearm intended for menthol / capsaicin administration) confirmed by routine neurological bed-side testing.
  6. Female subjects must be postmenopausal (with at least 2 years since last menstruation), surgically sterile (e.g., after hysterectomy or bilateral oophorectomy), or practicing an effective method of birth control (e.g., oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) at the Enrollment Visit and during the trial.
  7. Female subjects of childbearing potential must have a negative serum hCG test at the Enrollment Visit.

Exclusion Criteria:

  1. The subject has received any of the IMPs or used an investigational medical device within 30 days or within a period less than 10 times the half life of an investigational drug, whichever is longer, before the first dose of IMP is scheduled.
  2. History or presence of opioid abuse, drug abuse, or alcohol abuse or presence of an acute intoxication with alcohol, hypnotics, centrally acting analgesics, or psychotropic drugs.
  3. Positive or missing drugs of abuse screening (alcohol breath test, urine screening test for drugs of abuse).
  4. Diseases or conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  5. History or presence of severe respiratory depression with hypoxia and/or hypocapnia, severe chronic obstructive pulmonary disease, cor pulmonale, severe bronchial asthma, paralytic ileus.
  6. History or presence of hypersensitivity to Tapentadol, menthol, capsaicin/chili peppers or any of the other excipients of the Palexia® IR (Tapentadol), menthol, or capsaicin formulations or to opioid antagonists (e.g., naloxone).
  7. Subjects who have used any prescribed and non-prescribed systemic or topical medication, except contraceptives, on a daily base within 14 days before the Enrolment Visit, or anticipated use from the Enrolment Visit until the first administration of the IMP.
  8. History or presence of seizure disorder and/or epilepsy or any condition associated with a significant risk for seizure disorder or epilepsy.
  9. History of orthostatic hypotension.
  10. Blood donation or acute loss of blood (more than 100 mL) during the 1 month before the enrollment visit, or intention to donate blood or blood products during the trial or within 1 month following the completion of the trial.
  11. Pregnant or breastfeeding women.
  12. Known or suspected of not being able to comply with procedures described in the trial protocol.
  13. Not able to communicate meaningfully with the investigator and staff.
  14. Preplanned surgery or procedures that would interfere with the conduct of the trial.
  15. Acute skin disease, lesions, acute sunburn, extensive tattoos or scars at the forearm where the menthol / capsaicin application is planned.
  16. Employee of the Investigator or trial site, with direct involvement in the proposed trial or other trials under the direction of that Investigator or trial site, as well as family members of the employees or the Investigator
  17. Administration of a monoaminoxidase-inhibitor (MAO-Inhibitor) within 14 days prior to recruitment visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01615510

Locations
Germany
Department of Neurology
Kiel, Germany, 24105
Sponsors and Collaborators
University of Schleswig-Holstein
Investigators
Principal Investigator: Ralf Baron, Professor Head of Division of Neurological Pain Research and Therapy
  More Information

No publications provided

Responsible Party: Ralf Baron, Professor Dr., head of division of neurological pain research and therapy, University of Schleswig-Holstein
ClinicalTrials.gov Identifier: NCT01615510     History of Changes
Other Study ID Numbers: TapCapMentho01
Study First Received: June 6, 2012
Last Updated: March 25, 2014
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Hyperalgesia
Somatosensory Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Capsaicin
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Antipruritics
Dermatologic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 29, 2014